Senate Dems’ Inhaler Pricing Probe Adds Fuel To FTC Patent Listing Press

By Gabrielle Wanneh / January 9, 2024 at 7:07 PM
Senate health committee Democrats are adding pressure on the country’s top four inhaler manufacturers to stop using patent tactics that stave off competition for inhalers and keep prices high, piggybacking on recent Federal Trade Commission (FTC) warnings that drug makers could face enforcement action if they inappropriately list patents for inhalers and autoinjectors in FDA's Orange Book. The lawmakers wrote to the top inhaler makers Monday (Jan. 8) calling out their use of patent practices, including alleged improper Orange Book...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.